Acura Pharmaceuticals(ACUR)
$0.00+0.00 (+98.02%)
ACUR
Acura Pharmaceuticals financials statements
$0.00
At close:+0.00 (+98.02%)
Acura Pharmaceuticals (ACUR) Ratios
85 Followers
Acura Pharmaceuticals Ratios
ACUR's free cash flow for Q4 2021 was $-426.00K. For the 2021 fiscal year, ACUR's free cash flow was increased by $0.00 and operating cash flow was $-426.00K. See a summary of the company’s cash flow.
| Ratios | Dec 21 | Mar 21 | Dec 19 | Jun 19 | Dec 17 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.72 | 0.16 | 1.10 | 0.32 | 0.55 |
| Quick Ratio | 0.72 | 0.16 | 1.10 | 0.32 | 0.55 |
| Cash Ratio | 0.13 | 0.05 | 0.80 | 0.06 | 0.48 |
| Solvency Ratio | -1.16 | -0.14 | -0.48 | -0.62 | -1.16 |
| Operating Cash Flow Ratio | -1.44 | -0.10 | -0.58 | -2.72 | -0.97 |
| Short-Term Operating Cash Flow Coverage | -22.48 | -0.12 | 0.00 | 0.00 | -1.67 |
| Net Current Asset Value | $ -310.00K | $ -6.45M | $ -6.13M | $ -5.31M | $ -2.06M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.23 | 3.61 | 2.34 | 1.96 | 0.59 |
| Debt-to-Equity Ratio | 1.12 | -1.06 | -1.27 | -1.17 | -99.78 |
| Debt-to-Capital Ratio | 0.53 | 16.58 | 4.77 | 6.96 | 1.01 |
| Long-Term Debt-to-Capital Ratio | 0.46 | -0.02 | 4.77 | 6.96 | 0.00 |
| Financial Leverage Ratio | 4.83 | -0.29 | -0.54 | -0.59 | -170.52 |
| Debt Service Coverage Ratio | -2.53 | -0.10 | -6.58 | -8.02 | -1.46 |
| Interest Coverage Ratio | -6.07 | -1.68 | -1.57 | -9.91 | -8.77 |
| Debt to Market Cap | 0.01 | 0.99 | 0.98 | 1.74 | 0.42 |
| Interest Debt Per Share | 0.01 | 0.22 | 0.24 | 0.22 | 0.21 |
| Net Debt to EBITDA | -0.23 | -9.25 | -1.69 | -1.31 | -0.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 94.24% | 99.94% | 99.92% | 99.57% | 95.68% |
| EBIT Margin | -43.44% | -21.23% | -124.65% | -840.73% | -176.03% |
| EBITDA Margin | -37.68% | -17.73% | -114.38% | -772.44% | -166.12% |
| Operating Profit Margin | -77.67% | -21.23% | -27.29% | -954.88% | -176.16% |
| Pretax Profit Margin | -56.24% | -33.84% | -142.04% | -937.07% | -196.12% |
| Net Profit Margin | -56.24% | -33.84% | -142.04% | -937.07% | -191.57% |
| Continuous Operations Profit Margin | -56.24% | -33.84% | -142.04% | -937.07% | -191.57% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 97.68% |
| EBT Per EBIT | 72.41% | 159.37% | 520.55% | 98.14% | 111.33% |
| Return on Assets (ROA) | -102.21% | -69.59% | -147.31% | -178.53% | -123.41% |
| Return on Equity (ROE) | -493.82% | 20.51% | 79.60% | 106.22% | 21044.44% |
| Return on Capital Employed (ROCE) | -351.88% | 13.10% | -48.72% | -546.03% | 19351.85% |
| Return on Invested Capital (ROIC) | -295.38% | -200.53% | -48.72% | -546.03% | -191.37% |
| Return on Tangible Assets | -102.21% | -72.64% | -215.41% | -338.50% | -168.11% |
| Earnings Yield | -4.00% | -19.05% | -61.41% | -158.13% | -88.47% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.89 | 5.69 | 13.70 | 2.01 | 41.77 |
| Payables Turnover | 0.47 | 57.45 | 0.01 | 0.00 | 42.67 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.57 | 7.38 | 4.92 | 0.68 | 4.37 |
| Asset Turnover | 1.82 | 2.06 | 1.04 | 0.19 | 0.64 |
| Working Capital Turnover Ratio | -0.48 | -1.14 | -6.11 | -0.27 | 16.57 |
| Cash Conversion Cycle | -741.77 | 57.75 | -57451.75 | -125358.47 | 0.18 |
| Days of Sales Outstanding | 36.90 | 64.11 | 26.65 | 181.61 | 8.74 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 778.67 | 6.35 | 57478.41 | 125540.08 | 8.55 |
| Operating Cycle | 36.90 | 64.11 | 26.65 | 181.61 | 8.74 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.18 | -0.28 |
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.18 | -0.28 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -3.71 | -0.11 | -0.10 | -0.93 | -1.67 |
| Operating Cash Flow to Sales Ratio | -0.47 | -0.20 | -0.23 | -9.53 | -1.52 |
| Free Cash Flow Yield | -3.38% | -11.34% | -10.06% | -160.84% | -70.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -25.00 | -5.25 | -1.63 | -0.63 | -1.13 |
| Price-to-Sales (P/S) Ratio | 14.06 | 1.78 | 2.31 | 5.93 | 2.17 |
| Price-to-Book (P/B) Ratio | 123.46 | -1.08 | -1.30 | -0.67 | -237.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -29.62 | -8.82 | -9.94 | -0.62 | -1.42 |
| Price-to-Operating Cash Flow Ratio | -29.62 | -8.82 | -9.94 | -0.62 | -1.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.50 | 0.07 | 0.07 | 0.01 | 0.03 |
| Enterprise Value Multiple | -37.54 | -19.27 | -3.71 | -2.07 | -1.40 |
| Enterprise Value | 22.11M | 12.20M | 11.28M | 6.56M | 6.90M |
| EV to EBITDA | -37.54 | -19.27 | -3.71 | -2.07 | -1.40 |
| EV to Sales | 14.15 | 3.42 | 4.25 | 16.01 | 2.33 |
| EV to Free Cash Flow | -29.80 | -16.97 | -18.26 | -1.68 | -1.53 |
| EV to Operating Cash Flow | -29.80 | -16.97 | -18.26 | -1.68 | -1.53 |
| Tangible Book Value Per Share | 0.00 | -0.20 | -0.21 | -0.22 | -0.08 |
| Shareholders’ Equity Per Share | 0.00 | -0.20 | -0.18 | -0.17 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Revenue Per Share | 0.04 | 0.12 | 0.10 | 0.02 | 0.19 |
| Net Income Per Share | -0.02 | -0.04 | -0.14 | -0.18 | -0.36 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.98 |
| Interest Burden | 1.29 | 1.59 | 1.14 | 1.11 | 1.11 |
| Research & Development to Revenue | 0.98 | 0.50 | 0.57 | 4.29 | 1.25 |
| SG&A to Revenue | 0.80 | 0.71 | 0.71 | 6.26 | 0.00 |
| Stock-Based Compensation to Revenue | 0.04 | 0.01 | 0.04 | 0.56 | 0.17 |
| Income Quality | 0.84 | 0.60 | 0.16 | 1.02 | 0.79 |
Currency in USD

